Founded as a spin-off of VUB, one of Flanders’ universities, in 2013, eTheRNA Immunotherapies specializes in mRNA technology. The company does not yet have a treatment on the market. Various clinical studies, including candidate therapies for the treatment of cancer and infectious diseases like malaria, are currently ongoing.
You are here
Flanders-based mRNA expert eTheRNA raises EUR 39 million
Operations Director Bernard Sagaert, who is acting as the new interim CEO of eTheRNA Immunotherapies, notes that the company is also shifting its strategic focus: “We are now seeking partners for further development after an initial phase of clinical research. We are focusing on our technology platforms to help partners with their development of mRNA therapeutics. This involves technology for the production of active molecules or custom-made lipid nanoparticles.”
eTheRNA Immunotherapies is just one of the many companies that make Flanders’ business and research ecosystem for life sciences & health so successful. Want to unravel this ecosystem in a virtual yet interactive way? Head to the Flanders360 platform and discover 300+ successful companies, universities, R&D centers, incubators and other players active in Flanders’ life sciences & health industry.
Alternatively, check out our industry overview to learn more about the available tax, legal and other incentives for establishing your life sciences & health hub in Flanders.